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Despite major advances in neuroimaging, no lesion is visualized on MRI in up to a quarter
of patients with drug-resistant focal epilepsy presenting for presurgical evaluation. These
patients demonstrate poorer surgical outcomes than those with lesion seen on MRI. Accu-
rate localization of the seizure onset zone (SOZ) is more difficult in MRI-negative patients
and often requires invasive EEG recordings. Positron emission tomography (PET) and mag-
netoencephalography (MEG) have been proposed as clinically relevant tools to localize
the SOZ prior to intracranial EEG recordings. However, there is no consensus regarding
the optimal gold standard that should be used for assessing the performance of these
presurgical investigations. Here, we review the current knowledge concerning the use-
fulness of PET and MEG for presurgical assessment of MRI-negative epilepsy. Beyond
the individual diagnostic performance of MEG and of different PET tracers, including [18F]-
fluorodeoxyglucose, [11C]flumazenil, and markers of 5-HT1A receptors, recent data suggest
that the combination of PET and MEG might provide greater sensitivity and specificity than
that of each of the two individual tests in patients with normal MRI.
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INTRODUCTION
Patients’ selection for epilepsy surgery is a two-step procedure that
first aims to identify potential candidates for presurgical evalua-
tion, and then to determine in each assessed individual whether
benefit:risk ratio for surgery is acceptable (1). This process pri-
marily requires localizing the seizure onset zone (SOZ), i.e., the
minimum amount of brain tissue that should be resected to ren-
der the patient seizure-free. The identification of the SOZ results
from the integration of a set of arguments, particularly electro-
clinical data obtained during long-term video-EEG monitoring
and results of optimal high-resolution brain MRI (1). Identifica-
tion of a structural abnormality on brain MRI is of paramount
importance, since such abnormality usually represents the core of
the presurgical and surgical strategy. Post-operative seizure out-
come positively correlates with the presence of an epileptogenic
brain lesion on MRI (2). Despite major advances in neuroimag-
ing, MRI remains negative in up to a quarter of patients presenting
for presurgical evaluation (3). Poorer surgical outcome in patients
with MRI-negative partial epilepsy partly reflects the difficulties
for determining the exact localization and extension of the SOZ. In
these patients, intracranial EEG recording is usually mandatory to
ensure the delineation of the SOZ. Whatever the invasive recording
technique used, subdural electrodes or stereoelectroencephalog-
raphy (SEEG), brain sampling remains limited by safety issues.
The placement of subdural or depth electrodes should therefore
be individualized according to the most possibly precise and reli-
able hypothesis regarding the localization of the SOZ. Overall, the
outcome of invasive EEG monitoring primarily depends on the
quality and interpretation of the non-invasive data used to decide
of the brain regions to be targeted.
Positron emission tomography (PET) and magnetic source
imaging (MSI) have been proposed as valuable tools to help local-
izing the SOZ prior to intracranial EEG recordings. However,
the comparative performance of these presurgical investigations
remains controversial, especially in patients with MRI-negative
epilepsy. On the other hand, recent data suggest that PET and
magnetoencephalography (MEG) might be complementary, with
their combination yielding increased sensitivity and specificity as
compared to each test used in isolation. Here, we review the cur-
rent knowledge concerning the usefulness of PET and MEG for
presurgical assessment of MRI-negative epilepsy and discuss the
impact of combining their results on SOZ localization.
PET STUDIES IN MRI-NEGATIVE FOCAL EPILEPSY
Several PET tracers have been evaluated as potential markers
of the SOZ in patients with epilepsy. [18F]-fluorodeoxyglucose
([18F]-FDG), which brain accumulation reflects the local cerebral
metabolic rate of glucose, is the most widely used tracer in patients
with epilepsy (4). However, multiples other tracers that target neu-
rotransmitter systems have also been studied in epilepsy, primarily
those labeling GABAA and 5-HT1A receptors (1).
Before discussing the individual diagnostic performance of
these tracers, some general methodological points should be
underscored: (i) whatever the radiotracer used, PET data are usu-
ally obtained during the interictal period. Although programing
ictal PET is feasible (5), its constraints, related to radioligands
kinetics and images acquisition, usually overcome its potential
benefit in daily practice. Possibility of seizure occurrence during
“interictal” PET acquisition should however be taken into account
since this might result in false lateralization of PET abnormality;
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(ii) PET findings should be assessed with reference to struc-
tural imaging, especially in patients with normal MRI. Indeed,
PET/MRI coregistration allows to more easily distinguish true
hypometabolism from the sole impact of focal atrophy or wide sul-
cus, and to detect subtle MRI abnormalities which would not have
been recognized otherwise. It has been shown that [18F]-FDG-
PET/MRI coregistration in patients with focal cortical dysplasia
(FCD) improved detection of focal metabolic abnormalities by
35–40%, both in patients with abnormal and normal MRI (6).
A study in children with MRI-negative epilepsy also reported
that coregistered [18F]-FDG-PET/MRI data resulted in the detec-
tion of subtle MRI abnormalities not previously recognized in 9
out 31 patients (7); (iii) interpretation of PET images primar-
ily relies on standard visual analysis, but statistical analysis, with
the widely used Statistical Parametric Mapping (SPM) software,
might improve the diagnostic yield of PET. Over the past years,
some authors have thus reported that the use of SPM can result
in greater sensitivity and specificity of PET imaging in patients
with MRI-negative epilepsy (8, 9). However, other studies did not
confirm this finding (10). In addition, various methodological pit-
falls of SPM analyses should be kept in mind, including artifacts
of various origins, presence of abnormalities in some control sub-
jects (11), and age difference between patients and controls (12).
In our clinical experience of more than 300 FDG-PET where both
visual and SPM analyses were performed, the latter proved use-
ful in two situations: (i) detecting subtle hypometabolism over
the mesial frontal or parietal regions, where spill-over and partial
volume effects often result in bilateral and symmetrical abnormal-
ities difficult to capture with visual analysis and (ii) demonstrating
the area of maximum hypometabolism in patients with multiple
or extensive visually detected abnormalities. Improvement in the
performance of SPM findings can be obtained by running such
voxel-based analysis on maps of asymmetry index between the
two hemispheres, rather than on the raw data (13).
[18F]-FDG-PET
Hypometabolism on interictal [18F]-FDG-PET is a hallmark of the
SOZ as well as surrounding areas (4). Several studies have evalu-
ated the sensitivity and specificity of [18F]-FDG-PET in patients
with MRI-negative focal epilepsy (see Table 1).
[18F]-FDG-PET abnormalities were observed in a majority of
patients, both in adults and children. In the largest cohorts, abnor-
mal PET was reported in 53–100% of patients (7, 12, 17, 20, 22,
27). However, the congruence between PET findings and the SOZ
localization was generally low. Although abnormalities usually
showed concordant lateralization with the SOZ, non-localizing
multilobar abnormalities, or falsely localizing abnormalities were
reported in up to 50% of patients (7, 16, 19, 20, 22, 29). Fur-
thermore, in patients with focal abnormality, the hypometabolic
area was frequently more widespread than the SOZ (7, 14, 16, 17,
26), although remote abnormalities appeared to be related to the
location of the primary seizure focus (14, 17). In a cohort of 61
patients with temporal or extra-temporal MRI-negative epilepsy,
where intracranial EEG was used as a gold standard to localize
Table 1 | Diagnostic accuracy of [18F]-FDG-PET in MRI-negative focal epilepsy.
Study Epilepsy Age group Number of
patients
Abnormal PET
findings (%)
Specificity of PET abnormalities Remarks
Concordant
lateralization
with the SOZ (%)
Focal hypometabolism
concordant with the
localization of SOZ (%)
Juhasz et al. (14) T, ET Children and adults 9 100 100 11 –
O’Brien et al. (15) T, ET Adults 36 – – 69.4 –
Hong et al. (16) T, ET Children and adults 28 57.1 57.1 42.9 –
Carne et al. (17) T Adults 30 – 86.7 33.3 –
Chapman et al. (18) T, ET Children and adults 24 – 66.7 66.7 –
Lee et al. (19) ET Children and adults 79 – 44.3 – –
Bien et al. (20) T, ET Adults 17 58.8 – 29.4 –
Jayakar et al. (21) T, ET Children 10 100 – 60 –
Knowlton et al. (22, 23) T, ET Children and adults 64 85.2 – 29 –
Brodbeck et al. (24) T, ET Children and adults 9 77.8 77.8 55.5 –
Immonen et al. (25) T Adults 17 – 58.8 – –
Rubi et al. (7) ET Children 31 67.7 58.1 32.2 –
Seo et al. (26) ET Children 14 100 71.4 21.4 –
Chassoux et al. (10) T,ET Children and adults 23 95.6 95.6 59.1 Taylor-type
FCD
LoPinto-Khoury et al. (27) T Adults 46 100 100 – All included
patients had
PET+/MRI−
Gok et al. (28) T Adults 38 – 84.1 6.7 –
T, temporal lobe epilepsy; ET, extra-temporal epilepsy; SOZ, seizure onset zone.
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the SOZ, [18F]-FDG-PET sensitivity, and specificity were 39.5%
(95% CI: 31.4–47.4) and 53.3% (95% CI: 30.0–76.0), respectively
(22). When the resected area of the 51 patients with Engel class
I surgical outcome served as a reference for defining the SOZ,
[18F]-FDG-PET sensitivity, and specificity increased to 59% (95%
CI: 47.4–67.4) and 79% (95% CI: 58.7–92.5), respectively (23).
The concordance between [18F]-FDG-PET data and the SOZ was
particularly low in patients with extra-temporal SOZ. Accordingly,
sensitivity of [18F]-FDG-PET to detect focal hypometabolism con-
cordant with the SOZ and to predict seizure outcome was <40%
in the majority of studies which evaluated patients with extra-
temporal epilepsy (7, 8, 16, 22, 26). However, two situations,
in which the diagnostic accuracy of [18F]-FDG-PET in patients
with MRI-negative epilepsy might be higher, should be individ-
ualized: (i) patients with mesial temporal lobe epilepsy without
evidence of hippocampal sclerosis on MRI; and (ii) patients with
MRI-negative Taylor-type focal cortical dysplasia.
In a series of 30 patients with MRI-negative temporal lobe
epilepsy, [18F]-FDG-PET showed abnormalities concordant with
SOZ localization in 26 patients (87%) (17). Among the subgroup
of 17 patients with focal hypometabolism on [18F]-FDG-PET who
had undergone temporal lobe surgery, 15 (88%) were seizure-free
after a mean post-operative follow-up of 38 months, a surgical
outcome similar to that observed in a control group that included
patients with hippocampal sclerosis on MRI (17). Interestingly,
the authors individualized some clinical differences between the
two patient’s groups. Those with MRI-negative PET-positive tem-
poral lobe epilepsy demonstrated lower frequency of history of
febrile convulsions and of hippocampal sclerosis at pathological
examination, but more widespread hypometabolism than those
with hippocampal sclerosis on MRI (17). In a larger series of 46
patients with MRI-negative TLE and unilateral temporal hypome-
tabolism on PET, 5-years seizure-free rate was 75%, versus 78% in
the 147 patients with MRI signs of mesial temporal sclerosis (27).
Among patients with extra-temporal MRI-negative epilepsy,
those with MRI-occult FCD demonstrate better post-operative
seizure outcome than those with normal pathological examina-
tion of the surgical specimen (2, 30). Whether or not detected on
MRI, Taylor-type FCD are typically associated with clearcut focal
hypometabolism on [18F]-FDG-PET at the site of the malforma-
tion (10, 31, 32). In a recent study of 23 patients with histologically
proven Taylor-type FCD and negative MRI, [18F]-FDG-PET dis-
closed a focal or regional hypometabolism in 22 patients (96%),
20 of whom were seizure-free post-operatively (10). Correlation
with SEEG data in 20 patients showed that hypometabolic zones
restricted to a single gyrus usually matched with the underlying
epileptogenic FCD, whereas larger hypometabolic areas included
the epileptogenic FCD but also cortical regions not involved at
seizure onset. However, the detection of small hypometabolic areas
associated with MRI-occult FCD can be challenging in some of
the typical locations of such FCD, such as the bottom of the F1–F2
sulcus, if not appropriately oriented by electro-clinical data.
Overall, MRI-negative patients can be separated into two
groups: (1) those with TLE or MRI-occult Taylor-type FCD where
[18F]-FDG-PET demonstrates high sensitivity and specificity asso-
ciated with excellent surgical outcome and (2) those with other
types of MRI-negative drug-resistant partial epilepsy where both
[18F]-FDG-PET and surgery proved less effective. This raises the
issue as to whether normal or not clearly localizing [18F]-FDG-
PET (i.e., multifocal or multilobar hypometabolism with unclear
borders) should be interpreted as a reliable indicator of a very poor
surgical prognosis, rather than as a limitation of PET.
RADIOLIGANDS OF RECEPTORS
Imaging of GABAA receptors
11C-flumazenil ([11C]-FMZ) is a selective antagonist of GABAA –
benzodiazepine (BZD) receptors (4). The BZD receptors labeled
with [11C]-FMZ represent modulator sites of the GABAA recep-
tors, which are primarily expressed post-synaptically on the apical
dendrites of neurons. A reduced FMZ binding, as observed in
patients with partial epilepsies, is thought to primarily reflect
an underlying neuronal loss. However, it has been shown that
[11C]-FMZ PET can demonstrated transient and falsely lateral-
izing asymmetries, possibly reflecting seizure-related short-term
plasticity of BZD receptors (33). In a test-re-test [11C]-FMZ PET
study, significant seizure-related variations were observed in 5 out
of 10 patients, including all three with MRI-negative temporal lobe
epilepsy (34).
Several studies have evaluated the clinical utility of [11C]-FMZ
in patients with MRI-negative focal epilepsy. Most studies eval-
uated [11C]-FMZ PET as a marker of the SOZ and compared it
with [18F]-FDG-PET. In 2004, a review of the literature identi-
fied 45 patients with TLE and a normal MRI who had undergone
[11C]-FMZ PET (35). [11C]-FMZ PET was abnormal in 38 patients
(84%), but these abnormalities were considered as surgically infor-
mative in only 21 of them (47%). Similar results were observed
in patients with extra-temporal epilepsy where [11C]-FMZ PET
detected abnormalities in 73 out of 102 retrieved cases, includ-
ing 52 which were judged as clinically relevant (35). Some studies
suggested that [11C]-FMZ PET sensitivity and specificity might
be greater than that of [18F]-FDG-PET in patients with MRI-
negative epilepsy of both temporal and extra-temporal origin (14,
36, 37). However, other studies did not confirm these findings
(29, 38). [11C]-FMZ PET has also been proposed to detect subtle
MRI-occult cortical microdysgenesis, specifically heterotopic neu-
rons within the periventricular white matter (39–41). However, it
should be noted that most [11C]-FMZ PET studies in patients with
MRI-negative epilepsies were performed more than 10 years ago,
using less optimal MRI investigations than those currently avail-
able, raising the possibility that subtle MRI abnormalities might
have been overlooked. One exception is a recent study that has used
[18F]-FMZ instead of [11C]-FMZ, and reported correct localiza-
tion of [18F]-FMZ abnormalities in 42% of patients with normal
MRI, in comparison with 58.8% with [18F]-FDG-PET (42).
Imaging of 5-HT1A receptors
Three different 5-HT1A receptors antagonist have been used in
epilepsy: [11C]WAY 100635, [18F]FCWAY, and [18F]MPPF (11).
PET studies with either of these ligands showed a high level
of binding in limbic (hippocampus, amygdala, parahippocam-
pal gyrus) and paralimbic (temporal pole, insula, anterior, and
posterior cingulate gyri) regions as compared with other neocor-
tical areas (43). In patients with mesial TLE, decreased binding
of all three tested tracers was consistently observed within the
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epileptogenic mesial temporal structures (4), with correlation
between the degree of binding reduction and epileptogenicity as
evaluated by intracranial EEG recording (44).
A limited number of patients with MRI-negative temporal
lobe epilepsy have been investigated with 5-HT1A receptors PET.
The studies evaluating [18F]MPPF in patients with temporal lobe
epilepsy included a total of 10 patients with normal MRI, including
nine with mesial temporal SOZ and one with neocortical tempo-
ral seizure focus (45, 46). Among the nine patients with a mesial
SOZ, seven showed decreased [18F]MPPF within the epileptogenic
limbic structure, including one with normal [18F]-FDG-PET (45,
46). Voxel-based analysis of asymmetry index maps increased the
specificity of [18F]MPPF abnormalities (13).
Similar data were reported with both [18F]FCWAY and
[11C]WAY 100635. [18F]FCWAY has been evaluated in 12 patients
with MRI-negative TLE, nine of whom showed congruent abnor-
malities (75%) with intracranial EEG data or surgical outcome,
with a slightly better sensitivity than that of [18F]-FDG-PET (47).
Another six patients with MRI-negative epilepsy were evaluated
with [11C]WAY 100635. All showed decreased ipsilateral mesial
temporal binding potential of [11C]WAY 100635 (48), including
four with unremarkable [18F]-FDG-PET (48).
Overall, these studies suggest that PET study of 5-HT1A recep-
tors might be of interest in identifying or confirming temporal
lobe SOZ, particularly when other imaging modalities, includ-
ing [18F]-FDG-PET, are non-conclusive. Whether or not 5-HT1A
receptor PET might have an added value in patients with epilepsy
of extra-temporal origin remains to be investigated.
Other tracers
Among the other PET tracers evaluated in epilepsy, [11C]alpha-
methyl-tryptophan (AMT) has a specific relevance in tuberous
sclerosis, by showing increased AMT uptake within the epilepto-
genic tuber, selectively (49). However, this pattern is only observed
in about half of patients in the majority of series, and in an
even lower proportion of patients in our personal experience
(50). Some studies have also shown abnormal AMT asymmetry
or increased AMT binding in the presumed SOZ in patients with
MRI-negative epilepsy, including a few cases with non-localizing
[18F]-FDG-PET (51–53).
MSI STUDIES IN MRI-NEGATIVE FOCAL EPILEPSY
MSI BASICS
Source localization of epileptic brain signals (such as epileptic
spikes, fast oscillatory signals, or focal background slowing) can
be used in the interictal period or during seizures using MEG.
Source modeling of those signals and subsequent coregistration
on individual brain MRI is referred to as MSI.
During the last 40 years, MEG instruments have evolved from
a single-channel portable system to the modern whole head sys-
tems with more than 300 channels that are housed in multilayered
shielded rooms. Moreover, validated source modeling procedures
are now available in several commercial softwares, so that routine
clinical use of MSI is now feasible (54–56).
Magnetic source imaging of epileptic spikes require several
sequential steps (55, 57, 58): (i) recording of pathological sig-
nals with MEG; (ii) preprocessing of MEG data (artifact detection
and removal, filtering, visual, or automatic detection of epileptic
spikes, averaging or not of epileptic spikes to increase signal-to-
noise ratio); (iii) modeling the conduction volumes of the brain
using brain MRI tissue segmentation (spherical head models or
more realistic head models which take into account individual
brain geometry and possible conduction anisotropies between dif-
ferent brain elements); (iv) resolving the so-called inverse problem
(i.e., determining the exact location of the neural source(s) best
accounting for the recorded MEG data); and (v) co-registrating
anatomical MRI data and functional data (brain sources of epilep-
tic spikes). The choice of the conduction and inverse models
is important as both solutions have a potential impact on MSI
results (59, 60).
Inverse models can be divided into three families. Most clinical
studies have used only the first family: classical single or multiple
dipole modeling in which a current dipole source model is fitted
to the MEG data. Parameters that have to be estimated are the
dipole position and strength. The second and third families have
been used much less. In the second family [example of methods:
MUSIC (61), beamforming (62)], a source is found by scanning
all possible positions in the brain. These methods require assump-
tions about which part of the measured data is signal and which
is background or noise. The third family [examples of methods:
LORETA (63) or MEM (64)], consists of linear inverse methods
in which the data are modeled with only the source strengths as
parameters for a distributed set of dipoles at known locations.
Assumptions about or constraints on source strength are required
for these methods.
The theoretical background of each inverse model is well known
but studies comparing the location accuracy of all methods in clin-
ical setting are lacking. Recently,de Gooijer-van de Groep et al. (65)
showed that three well known inverse methods (MUSIC, SAMg2,
and LORETA) had approximately the same localization accuracy,
but that their sensitivity depended on the anatomical location of
spike sources. The authors advised to use a combination of those
methods in clinical practice.
Magnetic fields recorded by MEG are almost uninfluenced by
variation in tissue conductivities (55, 66). Thus, simple models of
the volume conductor for MEG source analysis offer high spatial
resolution with only minimal distortion (60). In contrast, EEG
recordings are more sensitive to volume currents. This explains
why more complex models, derived from individual anatomy, are
needed for optimal EEG source analysis, and why the latter is more
prone to localization errors due to inaccurate segmentation of the
brain compartments associated with distinct conductivity. This is
especially relevant for patients with large brain lesions or malfor-
mations, and those who have undergone prior brain surgery. MEG
also suffers limitations, being insensitive to exclusively radially ori-
ented sources, such as those found at the depth of sulci or top of
gyri (55, 66). As a consequence, activity from radial sources may be
overlooked, while those from oblique source will suffer reduction
in amplitude.
Magnetoencephalography benefit from high temporal resolu-
tion of less than a millisecond and, under optimal circumstances,
spatial resolution of several millimeters (66). However, precisely
estimating the accuracy of MSI localization would require ref-
erence information as to the actual source location of epileptic
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paroxysmal transients, which is seldom the case. The degree of
inaccuracy may be calculated directly by modeling simulated data
from known sources, or alternatively by creating current dipoles
between two adjacent intracerebral electrodes in vivo. A mean
localization error of about 10 mm may be accepted, but this can
vary from a few millimeters to as much as a few centimeters. Indeed
it is generally well accepted that the localization error: (i) is larger
when the source is deeply located; (ii) is smaller when realistic head
models are used, compared with spherical models; (iii) is smaller
when the spatial sampling of MEG captors is increased; and (iv)
decreases when the signal–noise ratio increases (66).
THE DIAGNOSTIC YIELD OF MSI IN MRI-NEGATIVE PATIENTS
Evaluating the diagnostic yield of MSI requires to evaluate the sen-
sitivity of the method and its accuracy. During the last 15 years,
numerous studies have been performed to evaluate the sensitivity
of MEG for: (a) the detection of epileptic spikes and (b) the detec-
tion of localized and focal sources of spikes (see Table 1). The vast
majority of those studies have been performed in selected groups
of patients referred for MEG evaluation because scalp-EEG dis-
closed frequent interictal spikes. Therefore, the sensitivity of MSI
in the general population is not known. Moreover, very few of these
studies specifically investigated MSI in negative MRI patients.
Based on existing studies, the sensitivity of MSI for the detec-
tion of focal sources of spikes is estimated between 35 and 90%
(67–69). The wide range of sensitivity estimates is partly due to
the different methodological approaches used to determine the
spatial extent of spike sources. Most studies used spatial cluster-
ing of spikes modeled with single dipole models as an estimate of
the volumetric extent of spiking volumes (26, 68–70). However,
the extent of spikes’ cluster remains difficult to interpret since
it depends on multiple factors including: (1) the spatio-temporal
heterogeneity of spike’s MEG signal; (2) their signal- to-noise ratio;
and (3) the statistical stability of the solution (71). Other modeling
approaches have been proposed to overcome this limitation. Our
group assesses the volumetric sources of spikes based on a beam-
forming method, which has been validated using intracranial EEG
as a gold standard (Volumetric Imaging of Epileptic Spikes, VIES)
(71). Using that method, we found that 8 out of 21 patients had
focal sources of spikes while nine others had either lateralized
but non-focal or bilateral sources of spikes. In successfully oper-
ated patients (i.e., seizure-free post-operatively), the proportion
of those with focal sources of spikes on preoperative MEG varies
between 71 and 100% (26, 68–70). Chowdhury et al. proposed to
use the MEM source localization framework with realistic models
based on cortical parcels to localize spatially extended generators
(64). That study showed that methods implemented within the
MEM framework were sensitive to all spatial extents of the sources
ranging from 3 to 30 cm2, whatever were the number and size of
the parcels defining the model.
The localizing value of MSI to delineate the SOZ has been eval-
uated in several studies with various gold standards (see Table 2).
Those using intracranial EEG have reported high spatial congru-
ence between the center of spiking areas determined with MSI and
the SOZ, varying from 81 to 100% (26, 70, 72). The level of spatial
overlap between MSI volumes and SOZ is lower due to: (a) spiking
volumes determined with MSI are only a statistical model of the
true brain spiking volumes and (b) brain spiking areas are usually
more widespread than the true SOZ. The accuracy of MSI is higher
for focal spiking volumes than for more widespread epileptiform
paroxysms, since conventional modeling approaches with current
equivalent dipoles are not well adapted to model sources of wide-
spread abnormalities (71). For the latter, alternative methods using
distributed sources models or beamforming methods have been
proposed, but large-scale clinical validation is still lacking (71).
The accuracy of MSI is also higher for superficial cortical sources
with tangential orientation (e.g., neocortical areas of the frontal
or parietal lobes), than for deep sources with radial orientation.
Studies defining SOZ as the resected area in patients seizure-
free post-operatively have also reported high accuracy of MSI,
between 80 and 100% (26, 68, 70). However, the accuracy of MSI
should not be overestimated since only a minority of the single
source localizations corresponding to individual spikes are finally
included in the surgical resection. For example, Fischer et al. pro-
posed to generate statistical volumes from the sources of individual
spikes (77). Using that method, they showed that an average of
20% of the MEG volumes were included in the resection volumes.
Moreover, there was a correlation between a favorable outcome
and a high coverage of the MEG volumes by the resection vol-
ume. For patients with several clusters of spikes, seizure freedom
is not directly related to the proportion of clusters of spikes being
resected. As a whole, this suggests that MSI is a good indicator
of the site of surgical resection, although it is not yet possible to
delineate perfectly the cortical regions to be resected based on MSI
results only.
Several MEG studies have shown that the presence of a focal
spiking source was predictive of surgical success. A recent study
showed that the odds-ratio (adjusted for epilepsy and MRI classi-
fication) for MSI prediction of seizure-free outcome was 4.4 (23).
Tightly clustered spike dipoles were also associated with favorable
surgery outcome. Our group recently showed that the extent of
the spiking volume determined with MSI is predictive of likeli-
hood of successful localization of the SOZ using intracranial EEG
(70). For patients with a focal spiking volume, the SOZ defined by
SEEG was clearly localized in all cases and most patients (6/7, 86%)
had a good surgical outcome. Conversely, SEEG failed to delineate
a SOZ in 57% of patients with a lateralized spiking volume, and in
two patients with bilateral spiking volume.
COMBINATION OF PET AND MSI DATA DURING
PRESURGICAL EVALUATION
COMPARATIVE ADVANTAGES AND LIMITATIONS OF PET AND MSI IN
PATIENTS WITH MRI-NEGATIVE EPILEPSY
According to the data discussed above, the advantages and lim-
itations of PET imaging and MSI in the assessment of the SOZ
in patients with MRI-negative epilepsy appear comparable. Both
approaches show variable sensitivity among series, which could
be explained by differences in the population studied, selection
bias (e.g., operated patients or patients with clearcut spikes on
scalp-EEG selected for MEG), and various methods used for data
analysis. The presence of a single focal abnormality, either on
MEG or PET, is associated with a good surgical outcome. How-
ever, the spatial congruence between the volume of PET or MEG
abnormalities, and that of the SOZ, is far from perfect in many
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Table 2 | Diagnostic accuracy of MSI in MRI-negative focal epilepsy.
Study Lobe Channels Number of
patients
Inverse
model
Patients’
age
Sensitivity Accuracy
Minassian et al. (73) TL, ET 74/148 11 SDM 8–16 Focal MEG: 8/11 Congruence MEG/iEEG: 8/8
Surgery: 5/5 MEG good outcome prediction: 4/8
Congruence MEG/surgery: NA
RamachandranNair
et al. (67)
TL, ET 151 22 SDM 4–18 Focal MEG: 18/22 Congruence MEG/iEEG: NA
Surgery: 9/9 MEG good outcome prediction: 8/18
Congruence MEG/surgery: 18/22
Funke et al. (74) TL, ET 306 17 SDM 3–54 Focal MEG: 6/17 Congruence MEG/iEEG: NA
Surgery: NA MEG good outcome prediction: NA
Congruence MEG/surgery: NA
Seo et al. (26) TL, ET 275 14 Beamforming 3–18 Focal MEG: 11/14 Congruence MEG/iEEG: 9/11
Surgery: 6/7 MEG good outcome prediction: 6/9
Congruence MEG/surgery: 9/11
Heers et al. (75) ET 74 3 SDM 19–45 Focal MEG: 3/3 Congruence MEG/iEEG: 3/3
Surgery: 2/2 MEG good outcome prediction: 2/3
Congruence MEG/surgery: 3/3
Jung et al. (70) TL, ET 275 21 Beamforming 4–55 Focal MEG: 8/21 Congruence MEG/iEEG: 8/8
Surgery: 6/6 MEG good outcome prediction: 6/7
Congruence MEG/surgery: 7/7
Widjaja et al. (76) TL, ET 151 26 SDM 0.9–17.6 Focal MEG: 19/22 Congruence MEG/iEEG: NA
Surgery: 14/16 MEG good outcome prediction: 14/18
Congruence MEG/surgery: 18/22
Wilenius et al. (72) TL, ET 306 13 SDM 12–47 Focal MEG: 8/13 Congruence MEG/iEEG: 8/8
Surgery: 5/7 MEG good outcome prediction: 5/8
Congruence MEG/surgery: 7/22
Wu et al. (69) TL, ET 74/248 18 SDM 23–60 Focal MEG: 12/18 Congruence MEG/iEEG: NA
Surgery: 10/10 MEG good outcome prediction: 10/12
Congruence MEG/surgery: NA
patients. Overall, the diagnostic accuracy of these investigations
often remains insufficient to guide surgical decision without prior
intracranial EEG in patients with MRI-negative epilepsy. Con-
versely, both investigations appear useful to guide the placement of
depth or subdural electrodes, and help promoting an optimal sam-
pling of the SOZ by these electrodes. A few MEG studies specifically
investigated this issue (22, 78, 79). Knowlton et al. showed that MSI
indicated additional electrode coverage in 18 of their 77 patients
(not initially planed when MSI results were blinded but added
after MSI was unblinded). Thirty-nine percent of those patients
had seizures involving the additional electrodes implanted on the
basis of MSI findings (78). Similarly, several studies have suggested
that PET results might be useful to guide electrode placement and
to improve coverage of the SOZ (36, 80).
POTENTIAL DIAGNOSTIC ADDED VALUE OF THE COMBINATION OF PET
AND MSI DATA
Considering the diagnostic performance of MSI and PET imag-
ing, an important issue is to evaluate whether multimodal imaging
using a combination of the two techniques might improve the pre-
sumptive localization of the SOZ, as compared to each technique
used in isolation. Only two studies investigated this issue (23, 76).
Knowlton and colleagues studied the localizing value of associa-
tion of MSI and [18F]-FDG-PET in 51 patients with MRI-negative
epilepsy who had achieved seizure freedom after epilepsy surgery
(23). The proportion of patients with localized abnormalities on
both MSI and [18F]-FDG-PET was low, with a combined sensitiv-
ity of 25% (95% CI 15.2–28.0). However, this diagnostic criterion
was highly specific: 95% specificity for MSI+PET in comparison
with 79% (58.7–92.5) for MSI or PET alone (23). In addition,
when associated with intracranial EEG data, the localizing accu-
racy of [18F]-FDG-PET-MSI combination reached 100% (23). The
other study included 22 children with MRI-negative epilepsy and
showed similar results (76). When both [18F]-FDG-PET and MSI
demonstrated abnormalities concordant with the cortical resec-
tion, specificity for Engel I seizure outcome was 100% (95.7–100)
whereas sensitivity of the combination was lower than that of
individual tests (55.0%) (76).
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FURTHER RESEARCH ISSUES
Despite these encouraging results, several issues remain to be
addressed. The exact impact of combining MSI and PET on the
placement of intracranial electrode, the final surgical decision, and
the post-operative outcome has not been specifically investigated.
According to the above studies, a positive impact is expected but
still needs to be demonstrated and quantified in various popu-
lations (e.g., TLE and extra-temporal epilepsy). For instance, the
sensitivity and the specificity of [18F]-FDG-PET in MRI-negative
patients appears higher in TLE than in extra-temporal epilepsy,
while the intrinsic characteristics of MSI result in higher accuracy
in neocortical epilepsy than in deeply located epileptic foci, such
as those responsible for mTLE. Combination of both tests might
improve SOZ localization in both situations, but also requires care-
ful interpretation of potential discordances between PET and MSI.
In neocortical epilepsy, where [18F]-FDG-PET abnormalities are
frequently more widespread than the SOZ, the detection of a MEG
focus might help to refine the interpretation of PET images by
highlighting spatially concordant abnormalities that may be the
core of the epileptogenic network. In mesial temporal lobe epilepsy
where a MEG focus is not detected or falsely localized outside the
mesial temporal structure, second interpretation of MSI results
in light of PET data might be useful. Both PET and MEG were
found to help detecting subtle MRI abnormalities, and in partic-
ular small FCD, in patients previously considered MRI-negative
(7, 10, 72, 74, 75). Whether the combination of [18F]-FDG-PET
and MSI remains useful when one of the two investigations has
allowed to identified a MRI-occult FCD also needs to be addressed.
The combination of PET-MSI has been studied using [18F]-FDG-
PET only. As detailed previously, other PET tracers might have
greater sensitivity and specificity than [18F]-FDG-PET in spe-
cific situations (i.e., 5-HT1A receptors PET in TLE). It might thus
be worth investigating the combination of MSI with these other
tracers.
CONCLUSION
Positron emission tomography and MSI have been proposed as
valuable tools to help localizing the SOZ prior to intracranial EEG
recordings. However, each of these techniques suffers from limi-
tations which might hamper a precise delineation of the SOZ in
patients with MRI-negative focal epilepsy. Combination of PET
and MEG might increase the sensitivity and specificity relatively
to individual diagnostic tests in these patients, an issue which still
needs to be formally demonstrated.
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